Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spin

Escribá PV, Gil-Agudo ÁM, Vidal Samsó J, Sánchez-Raya J, Salvador-de la Barrera S, Soto-León V, León-Álvarez N, Méndez Ferrer B, Membrilla-Mesa MD, Redondo Galán C, Benito-Penalva J, Montoto-Marqués A, Medel Rebollo J, Palazón García R, Gutiérrez Henares F, Miralles M, Torres M, Nieto-Librero AB, García Marco D, Gómez C, Jimeno D, Oliviero A.